Gilead (NASDAQ: GILD) CEO O’Day sells $19.69 million of stock from exercised options
by Tristan Rich · The Markets DailyWhat happened
Gilead Sciences, Inc. (NASDAQ: GILD) Chairman and CEO Daniel Patrick O'Day sold 112,429 shares on Nov. 4 and Nov. 5 for about $19.69 million.
The filing, dated Nov. 6, lists O'Day as both an officer and a director of the company. O'Day sold 102,619 shares on Nov. 4 and 9,810 on Nov. 5, at reported prices of $175.16 and $175.17 per share. The filing says individual trades ranged from $175.05 to $175.35.
Every share sold came from stock options exercised on the same day at $72.34 per share. The filing says the trades were made under a Rule 10b5-1 trading plan adopted on Feb. 25, 2026, and it checks the box saying the plan is intended to meet the affirmative defense conditions of Rule 10b5-1(c).
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 112,429 shares | SEC Form 4 | |
| Total sale value | $19.69 million | SEC Form 4 | |
| Reported sale price per share | $175.16 to $175.17 | SEC Form 4 | |
| Shares held after the sales | 551,683 shares | SEC Form 4 | |
| Shares sold as a share of the holding before the trade | 16.9% | Calculated from SEC Form 4 | |
| Stock options held after Nov. 5 | 128,310 options | SEC Form 4 |
Read more: Gilead Sciences (GILD) company research
Why it matters
Because the sold shares came from option exercises, O'Day's direct holding was 551,683 shares after the Nov. 4 sale and the same after the Nov. 5 sale.
By OptimistFi's calculation, the shares sold were 16.9% of the 664,112 shares held before the trade, a count that includes the shares received from the exercises. The options themselves fell to 138,120 after the Nov. 4 exercise and to 128,310 after the Nov. 5 exercise, and they expire March 10, 2030.
The options vest over four years, the filing says, with 25% vesting on the first anniversary of the grant and 6.25% each quarter after that.
OptimistFi has argued that Gilead turns a defended HIV franchise and strong operating cash flow into shareholder returns. A sale under a pre-set plan leaves that case unchanged. Because the plan was adopted earlier in the year, the sales are weak evidence either way about the company's prospects.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Gilead's next quarterly earnings report is the next test of the case. Steady HIV sales and operating cash flow would support OptimistFi's view, while a slowdown in either would weaken it.
More from OptimistFi
- GILD stock: research and coverage of Gilead Sciences
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
- Weekend market prices: US stock indexes, gold and oil now
Sources
- SEC Form 4, Gilead Sciences, Inc. (Daniel Patrick O'Day) — Statement of changes in beneficial ownership signed Nov. 6, 2026, covering transactions on Nov. 4 and Nov. 5, 2026.
Explore OptimistFi research on Gilead Sciences, Inc.: https://optimistfi.com/stocks/GILD
Browse Gilead Sciences, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Gilead Sciences, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.